HHS offers $2.5M in CARES Act funding to boost health information exchange during crises

Health and Human Services is making $2.5 million in funding available in a bid to boost health information exchange during this and future public health crises, the agency announced Wednesday.

The money comes by way of the Coronavirus Aid, Relief and Economic Security Act and is aimed at strengthening such data sharing between HIEs and public health agencies. HHS will award up to five grants as part of the program, with a Sept. 1 application deadline.

“State and local HIEs play a unique role in their communities by uniting health information from many different sites of service—including providers, hospitals, nursing homes, clinical laboratories and public health departments—making them a natural fit to deliver innovative, local ‘last mile’ approaches to strengthen our overall public health response,” Don Rucker, MD, national coordinator for health IT, said in a statement.

Those awarded funding must make a special effort to address populations hit hardest by the pandemic, with an eye on age, race, ethnicity, disability and sex, HHS added. You can read more about the funding opportunity here.

Marty Stempniak

Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.